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Abstract
Background:Decreased lung function is common in preterm-born survivors. Increased
fractional exhaled nitric oxide (FeNO) appears to be a reliable test for eosinophillic
airway inflammation especially in asthma. We, systematically, reviewed the literature
to compare FeNO levels in preterm-born children and adults who did or did not have
chronic lung disease of prematurity (CLD) in infancy with term-born controls.
Methods:Wesearchedeight databases up toFebruary2018. Studies comparingFeNO
levels in preterm-born subjects (<37 weeks’gestation) in childhoodandadulthoodwith
and without (CLD) with term-born subjects were identified and extracted by two
reviewers. Data were analysed using Review Manager v5.3.
Results: From6042 article titles, 183 full articleswere screened for inclusion.Nineteen
studiesmet the inclusion criteria. Seventeen studies comparedFeNO levels in preterm-
and term-born children and adults; 11 studies (preterm n = 640 and term n = 4005)
were included in a meta-analysis. The mean FeNO concentration difference between
the preterm-born and term-born group was −0.74 (95% CI −1.88 to 0.41) ppb. For the
six studies reporting data on CLD (preterm n = 204 and term n = 211) the mean
difference forFeNO levelswas−2.82 (95%CI−5.87 to0.22) ppbbetween thepreterm-
born CLD and term-born groups.
Conclusions:Our data suggest that preterm born children with and without CLD have
similar FeNO levels to term-born children suggesting an alternative mechanism to
eosinophilic inflammation for symptoms ofwheezing and airway obstruction observed
in preterm-born subjects.
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1 | INTRODUCTION
Adverse events in early life and their impact on longer term health and
morbidity are increasingly recognized.1 Preterm birth is a well-
recognized early adverse event, with potential lifelong health
implications. Approximately 11% of all infants are born prematurely
world-wide with rates increasing in many countries.2 Prediction and
prevention of preterm birth is currently limited thus characterizing the
long-term effects of preterm birth is vital to optimize their future
quality of life.
The lungs are one of the last major body system to mature in
utero, therefore, preterm infants are born with immature airway
structures with decreased gas exchange surface.3 Respiratory
pathology is the commonest consequence of preterm birth,
manifesting as neonatal respiratory distress syndrome, a conse-
quence of structurally immature lungs and pulmonary surfactant
deficiency. These infants often require ventilatory support, both
invasive and non-invasive, and supplementary oxygen. A subset of
these infants will go on to develop chronic lung disease of
prematurity (CLD),4 often defined as supplementary oxygen
requirement at 36 weeks’ corrected gestational age.5
Nitric oxide (NO) has several functions in the lung including
neurotransmission, vasodilatation, bronchial dilatation, and immune
enhancement. However, in diseases such as asthma, its actions can be
paradoxical. Animal studies have shown that at lower concentrations,
NO has a bronchodilator effect, but at higher levels NO has a pro-
inflammatory action. The increased levels of NO observed in disease
states caused by airway inflammation are thought to be the result of
increased induction of nitric oxide synthease and of increased reactive
nitrosylation pathways.6
Fractional exhaled nitic oxide (FeNO) has been demonstrated to
be a useful biomarker of eosinophilic airway inflammation. FeNO levels
can be easily measured non-invasively by a single-breath exhalation
technique and, through utilizing mathematical airway modelling, is
thought to provide a representation of distal airway inflammation.6
Although commonly thought of as an eosinophilic disease, airway
inflammation in asthma can also be neutrophilic in origin.7 FeNO levels
have been shown to be higher in children with asthma and during
asthma exacerbations, being associated with increased airway
inflammation.8 It was reported in a systematic review in 2017 that
FeNO is a reasonably accurate diagnostic test for identifying subjects
with asthma, with good specificity and acceptable sensitivity,9
especially in those with eosinophilic lung disease. FeNO is not only
widely used as a diagnostic tool, but serial measurements have also
been shown to be useful for monitoring treatment responses to
inhaled corticosteroids.10
Several studies have shown evidence of persistent abnormal lung
function in later childhood for infants diagnosed with CLD. In previous
systematic reviews, we have reported that preterm-born subjects have
deficits in FEV1, increased rates of bronchial hyper-responsiveness,
and single doses of bronchodilators appeared to improve FEV1.
11–13 It
has been reported that preterm-born subjects have higher rates of
wheezing and are often diagnosedwith asthma. The systematic review
by Been et al. reported increased rates of wheezing in preterm-born
subjects.14 In addition, we have reported increased rates of wheezing
in preterm-born children which was independent of a family history of
atopy.15 We would question the diagnostic labelling of preterm-born
subjects with the label asthma, especially as the mechanisms
underlying the deficits in lung function and increased rates of
bronchial hyper-responsiveness remain uncertain. We believe that
the mechanisms are likely to differ to asthma thus sought if FeNOwas
a useful diagnostic test for preterm-born children as it is for asthma.
Thus, we conducted a systematic review and meta-analysis to
identify:
a) if FeNO level is increased after preterm birth when compared to
term-born controls, and
b) if FeNO level is increased in preterm-born subjects who had CLD
compared to term-born subject.
2 | METHODS
We ran search strategies which included keywords relating to FeNO,
preterm-birth and study design in eight databases; and additionally we
searched references in the included articles to identify additional
papers reporting FeNO levels in preterm-born subjects compared to
term-born subjects (see Supplementary Protocol for protocol, search
strategy, and data collection table). The eight databases searchedwere
Webof Knowledge, Scopus, CINAHL,OpenSIGLE,Medline,Medline in
process, EMBASE, and HMIC. Ethical approval was deemed not
necessary.
2.1 | Eligibility criteria
Studies on FeNO levels in preterm-born children and adults subjects
over 2 years of age, with or without CLD compared to term-born
subjects were included. Preterm-born was defined as birth at <37
weeks’ gestation and term-born as birth at ≥37 weeks’ gestation. We
accepted the authors’ definitions of CLD. All methods of assessing
FeNO levels were accepted. However, only studies which reported the
concentration of FeNO in the preterm-born and a comparator term-
born groups were included. Studies in all languages from all countries
were considered.
2.2 | Study selection
Searches were carried out in February 2018. Two reviewers (SJK and
CC) independently screened each reference title and available
abstracts, using the inclusion criteria in the protocol. Any reference
title that met the inclusion criteria as judged by either CC or SJK was
then included in the next stagewhere the complete full manuscriptwas
obtained. SJK and CC then reviewed the full manuscript against the
inclusion criteria. Where there was agreement, the manuscript was
included in the next stage and data were extracted. Where there was
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disagreement, a third reviewer (SK) reviewed the complete manuscript
and arbitrated the final decision.
2.3 | Data collection process
SJK data extracted data from included articles into the data tables,
which were independently verified by CC. If data was not in a format
which enabled the data to be included in the systematic review, the
authors were contacted for further information wherever possible.
Where multiple manuscripts from the same cohort were identified,
they were reviewed by SJK and SK and a decision made about which
article should be included, based on the largest, most complete cohort.
2.4 | Outcome measures
FeNO level in the preterm-born subjects and in the preterm-born
subjects with CLD compared with a term control group.
2.5 | Analysis of results
A formal meta-analysis was conducted for the studies which reported
the mean and standard deviation, (or where they could be easily
obtained) of FeNO (a) in the preterm (with and without CLD) and
control groups, and (b) in the pretermwith CLD group and term control
group. The results of all the studies are also presented descriptively.
2.6 | Statistical analysis
Statistical analyses were performed using ReviewManager (RevMan)
Version 5.3.16 After initial exploration of the data, we used random
effects meta-analyses to allow for heterogeneity. Medians were
converted to means using the method of Wan et al. where enough
information was present to allow this to be calculated.17 A calculator
was used to convert 95% confidence intervals to standard
deviation.18 In addition, a sensitivity analysis was conducted: studies
where the means and standards deviations were calculated from
medians, and the single study where standard deviations were
calculated from 95% confidence intervals were removed from the
meta-analysis.
3 | RESULTS
3.1 | Studies selected and their characteristics
A total of 6042 article titles were identified of which 183 full articles
were screened for inclusion. Nineteen met the inclusion criteria
(Figure 1).19–37 For the three studies that overlapped data were kindly
supplied by the authors.32–34 In addition, a further author kindly
supplied their data so the study could be included.35 Demographics of
included articles are shown in Supplementary Table S1. Medians and
IQRs or ranges were converted to means and standard deviations for
three studies.23,25,28 Mean and 95% CI were converted to mean and
standard deviation for one study.24
3.2 | Study outcomes
3.2.1 | FeNO in preterm group compared to term
control group
From the 17 studies identified, 11 (preterm n = 640 and term n = 4005)
were included in a meta-analysis and 6 are described in detail below.
The results of the meta-analysis are shown in Figure 2. The mean
difference for FeNO level between the preterm-born and term-born
groupwas −0.74 (95%CI −1.88 to 0.41) ppb. The studies are described
in detail in Supplementary Table S1.
3.2.2 | FeNO in preterm group who had CLD in
infancy compared to term control group
From the 17 studies identified, 6 (preterm n = 204 and term n = 211)
were included in a meta-analysis as shown in Figure 3. The mean
FIGURE 1 Study selection results
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difference for FeNO levels between the preterm-born and term-born
groupwas −2.82 (95%CI −5.87 to 0.22) ppb. The studies are described
in detail in Supplementary Table S1.
3.2.3 | Sensitivity analysis
Removing the four studies where the means and/or standard
deviations were calculated from the meta-analysis reporting the
FeNO levels in the preterm group compared to the term group did
not alter the mean difference substantially (mean −0.92 (95% CI
−2.28 to 0.45) ppb. Removing the three studies where the means
and/or standard deviations were calculated from the meta-analysis
reporting the FeNO levels in the preterm group who had CLD in
infancy compared to the term group did alter the mean difference
substantially (−4.11 (mean 95% CI −10.72 to 2.50) ppb. However, by
removing the three studies, only three studies were left in the meta-
analysis and the number of preterm-born children dropped from 204
to 144, with the number of term-born children dropping from 211 to
134.
3.2.4 | Description of studies not included in the
meta-analyses
Six studies were not included in a meta-analysis. They are described in
detail in Supplementary Table S1 and briefly summarised below with
data for FeNO given in ppb. In general, the preterm-born subjects with
and without CLD compared to the term-born group had statistically
similar or lower levels of FeNOcompared to control groups.Mostwere
excluded as they either reported data as geometric means or as
medians.
1. Nordlund et al.19 studied 30 preterm-born children with CLD and
30 term born children with asthma sensitized to airborne allergens
at amean age of approximately 10 years and reported a significantly
lower FeNO level in the preterm-born children with CLD (median
FeNO in the CLD group 7.9, in the asthma group 13.3).
2. Baraldi et al.20 studied 31 preterm-born children with CLD, 31
preterm-born children without CLD, 31 term controls and 31
patients with asthma at an approximate mean age of 8 years. The
two preterm-born groups had the lowest FeNO levels when
FIGURE 2 Mean FeNO of the preterm-born group compared to the term-born group
FIGURE 3 Mean FeNO of the preterm-born group with CLD compared to the term-born group
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compared to the term controls and the patients with asthma. The
CLD group had statistically significantly lower levels of FeNO
compared to the other three groups (geometric mean FeNO in the
CLD group 7.7, term 10.7, preterm-born no CLD 9.9, asthma 24.9).
3. Kilbride at al.21 studied extremely low birth-weight preterm-born
children, heavier preterms and term-born children with a normal
birthweight at 12-15 years of age FeNO results did not differ by
birthweight category (FeNO in ELBW preterm-born children 10.2,
heavier preterm born children 15.2, and normal birthweight term-
born children 10.4).
4. Vollsaeter at al.30 also studied 45 preterm-born adults, who were
subdivided by CLD severity, and compared the CLD groups to 39
term-born, 18-25 year-old adults. FeNO levels did not differ
between the groups (geometric mean FeNO terms 11.8, No-CLD
11.7, Mild CLD 12.2, moderate/severe CLD 11.5).
5. Vollsaeter at al.36 studied preterm-born children with and without
CLD and term-born controls at a mean age of approximately
11 years. FeNO levels did not differ significantly between the
groups (geometricmean FeNO terms 11.77, preterm noCLD10.46,
preterm CLD 9.08).
6. Malmberg et al.37 studied very low birthweight children, children
with a history of wheeze and term-born children at 8-10 years of
age. The FeNO levels were not significantly different between the
groups once height was adjusted for (geometric mean FeNO terms
9.9, and VLBW 10.7).
4 | DISCUSSION
To our knowledge, this is the first systematic review andmeta-analysis
examining FeNO levels in preterm infants, with and without CLD,
compared to infants born at term. FeNO level is generally higher in
subjects with asthma, but especially in those who have eosinophilic
airway inflammation. FeNO has been established as a reliable, non-
invasive test for aiding the diagnosis of eosinophilic asthma, with
reasonable sensitivity and good specificity.9 A recent review studying
exhaled biomarkers summarized the evidence to date with the
statement that “FeNO is consequently considered a marker of a
common asthma endotype characterized by Th2-mediated airway
inflammation, eosinophilia, and responsiveness to inhaled steroids”.8
The results of our systematic review and meta-analyses suggest that
subjects born preterm have no statistically significant difference in
FeNO levels when compared to term-born subjects. Preterm-born
subjects with CLD also had similar results to term-born subjects. The
latter results should be treated with caution as the number of studies
and total number of subjects was smaller; and themean differencewas
altered by the removal of the studieswhere themeans and/or standard
deviations were calculated from medians or 95% CIs.
Despite improvements in neonatal management over the past
20 years, including the routine use of antenatal steroids, surfactant,
and gentle mechanical ventilation modes, CLD remains a significant
consequence of preterm birth at an immature stage of pulmonary
development. Preterm born infants are known to experience
long-term respiratory morbidity during the rest of childhood. Those
with a diagnosis of CLD aremost vulnerable. Preterm born infants with
and without CLD are more prone to wheezing symptoms, more
frequently use inhaled bronchodilator treatments, aremore likely to be
admitted to hospital for management of wheeze or dyspnoea, and are
more than twice as likely to be labelled with a diagnosis of asthma.38
This increased respiratory morbidity appears to extend beyond
childhood into adulthood.39 However, the reasons for continuing
respiratory illness in childhood and beyond remains unclear.
Our results suggest that preterm-born subjects are unlikely to
have eosinophilic airway inflammation underlying their respiratory
symptoms and may not have the same airway mechanics as those
childrenwith a diagnosis of asthma. The data suggest that theremay be
alternative underlying mechanisms to explain their episodic or chronic
wheezing and symptoms of airway obstruction. Whether that is
structural or functional remains to be confirmed; our recent systematic
review reported increased bronchial hyper-responsiveness in preterm-
born subjects compared to term-born subjects by both direct and
indirect methods of measuring bronchial hyper-responsiveness. When
only subjects who were preterm-born and had CLD in infancy were
studied, the differences were greater, suggesting greater pathology of
their airways.13 We have also reported increased exercise-induced
bronchial hyper-responsiveness in school-age children with a back-
ground of CLD which is responsive to bronchodilator therapy.40
With increasing number of children surviving preterm-birth, it is
important to understand the impact of preterm birth at a critical stage
of lung development. Currently, the mechanisms underlying the
increased respiratory symptoms, deficits in lung function, increased
bronchial hyper-responsiveness, responses to single doses of a
bronchodilator are not fully understood. Our data adds that airway
eosinophilic inflammation is unlikely since FeNO level was not
increased in the preterm groups including in those with CLD when
compared to their term counter-parts. However, FeNO may be
affected by abnormal lung development in patients with CLD, so it will
be difficult to exclude completely eosinophilic airway inflammation.
We have recently shown that preterm-born subjects may have specific
wheezing phenotypes.41 It may be that specific phenotypes are
associated with increased FeNO. There are suggestions that
neutrophilic or oxidant injury may be continuing but these small
studies need to be replicated including to identify the reasons why
such injury is continuing especially given that the initial injuries most
likely occurred perinatally.
The authors used various different methods to measure FeNO
and, importantly, used differing methods to represent their data
including as means, medians or geometric means; or as proportions of
children with greater than a predefined value of FeNO, most
commonly 35 ppb. This led to difficulty in interpreting the data
between the different studies. Thus, it is important in any future task
force where expert opinion is sought to include the most appropriate
way of reporting FeNO concentrations. Given that the data is unlikely
to be normally distributed, geometric means together with proportions
of childrenwith greater than predefined FeNO valuesmay be themost
appropriate way forward.
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5 | LIMITATIONS
As with all systematic reviews we were limited by the quality and
data supplied in the studies included in the meta-analysis. The data
was not always normally distributed hence many authors did not
present their results as means and standard deviations. We
converted medians where possible to means and standard devia-
tions, but this may have introduced errors. However, we carried out
a sensitivity analysis to explore this. In addition, the heterogeneity of
the studies included is also a limitation. There was heterogeneity due
to the fact the preterm and term-born subjects were born over a
number of years, were tested at a range of ages, and were born at a
range of gestations, during a period where standards of neonatal
intensive care and management of extreme prematurity have
changed, including the introduction of antenatal steroids and
surfactant. In addition, FeNO levels were not measured with same
make of device in all the included studies.
6 | CONCLUSION
Our systematic review and meta-analysis showed that infants born
preterm, both with and without CLD had similar FeNO values to term-
born controls. Despite preterm born children beingmore likely to show
wheezing symptoms and be labelled with a diagnosis of asthma, our
data suggests that their respiratory symptoms and airway obstruction
are unlikely to be mainly due to eosinophilic airway inflammation thus
unlikely to benefit from the diagnostic label of asthma. Future research
should aim to further the underlying mechanisms explaining the long-
term respiratory morbidity observed in preterm-born children and to
accurately identify biomarkers to tailor their treatments to their
specific respiratory pathology.
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